Merck & Co (NY:MRK)

139.54 -4.76 (-3.30%)

Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

July 14, 2025

From Merck & Co., Inc.

Via Business Wire

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial ↗

July 14, 2025

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a favorable safety profile.

Via Benzinga

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

P/E Ratio Insights for Merck & Co ↗

July 09, 2025

Via Benzinga

MERCK & CO. INC. (NYSE:MRK) – A Strong Dividend Stock with Solid Fundamentals ↗

July 11, 2025

MERCK & CO. (NYSE:MRK) offers a strong 4% dividend yield, consistent growth, and solid profitability, making it a top pick for income investors. The stock is also attractively valued.

Via Chartmill

2 Top Stocks Down 16% and 17% This Year to Buy and Hold ↗

July 11, 2025

Via The Motley Fool

Topics Intellectual Property

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

July 10, 2025

From Merck & Co., Inc.

Via Business Wire

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

July 10, 2025

From Merck Sharp & Dohme

Via Business Wire

Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps ↗

July 09, 2025

Kazia's early trial data show significant CTC and cluster reduction in a breast cancer patient treated with Paxalisib, Keytruda, and chemotherapy.

Via Benzinga

Nvidia's $4 Trillion Milestone Lifts Wall Street: What's Moving Markets Wednesday? ↗

July 09, 2025

Wall Street rose on Wednesday as investors shrugged off fresh trade uncertainty after the White House delayed the start of new tariffs to Aug. 1, raising hopes for new rounds of negotiations.

Via Benzinga

Topics World Trade

Explore the top gainers and losers within the S&P500 index in today's session. ↗

July 09, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verona Pharma plc (Nasdaq - VRNA), Olo Inc. (NYSE - OLO), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC)

July 09, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug ↗

July 09, 2025

Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss.

Via Benzinga

Topics Intellectual Property

Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma ↗

July 09, 2025

The takeover target just launched its first drug last summer. Shares have mostly trended higher since.

Via Investor's Business Daily

Topics Government

Merck To Acquire Verona For $10B In Bid To Expand Cardio-Pulmonary Pipeline ↗

July 09, 2025

Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

Via Stocktwits

Topics Government

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

July 09, 2025

From Merck & Co., Inc.

Via Business Wire

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)

July 08, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025

July 08, 2025

From Merck & Co., Inc.

Via Business Wire

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

July 07, 2025

Via Investor Brand Network

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

July 07, 2025

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

July 07, 2025

Via The Motley Fool

Topics Stocks

Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report ↗

July 04, 2025

Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies .

Via Benzinga

Topics Government

2 S&P 500 Stocks with Promising Prospects and 1 to Question

July 04, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

Uncover the latest developments among S&P500 stocks in today's session. ↗

July 03, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.

Via Chartmill

AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment ↗

July 03, 2025

Via Benzinga

What's going on in today's session: S&P500 gap up and gap down stocks ↗

July 03, 2025

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.

Via Chartmill

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

July 03, 2025

Via Benzinga

Merck's Hypertension Drug On FDA Fast Track For Label Expansion ↗

July 02, 2025

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

Via Benzinga

FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial

July 02, 2025

From Merck & Co., Inc.

Via Business Wire

MERCK & CO. INC. (NYSE:MRK) – A Strong Value Candidate in Healthcare ↗

July 02, 2025

MERCK & CO. (NYSE:MRK) is an undervalued pharmaceutical stock with strong profitability, a healthy balance sheet, and a reliable dividend, making it a candidate for value investors.

Via Chartmill

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.